GGrantIndex
Sort

53,477 grants matching addiction

EFFECTS OF NICOTINE YIELD & NICOTINE REPLACEMENT ON VERY LOW NICOTINE CONTENT CIG

$4,799,454
Eric Christian Donny · University Of Pittsburgh At Pittsburgh · U54 · FY2013 · DA

Tailored Retention and Engagement for Equitable Treatment of OUD and Pain (TREETOP)

$4,798,445
Jessica S Merlin · University Of Pittsburgh At Pittsburgh · RM1 · FY2021 · DA

ABCD-USA Consortium: Twin Research Project

$4,791,106
Monica M Luciana · University Of Minnesota · U01 · FY2017 · DA

Select Late-Stage CMC, Non-clinical Studies, and Quality Programs to Accelerate NRS-033 Towards Pivotal Studies and Registration in Opioid Use Disorder

$4,785,001
Nikej Shah · Nirsum Laboratories, Inc. · U01 · FY2024 · DA

Health Systems Node of the NIDA Clinical Trials Network

$4,774,238
Cynthia I Campbell · Kaiser Foundation Research Institute · UG1 · FY2020 · DA

PET Radiopharmaceutical Sciences

$4,765,174
Victor W Pike · National Institute Of Mental Health · ZIA · FY2023 · MH

HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers

$4,761,350
William C Becker · Yale University · RM1 · FY2021 · DA

GENERAL CLINICAL RESEARCH CENTER

$4,743,796
Peter L Slavin · Massachusetts General Hospital · M01 · FY2006 · RR

ABCD-USA Consortium: Twin Research Project

$4,720,631
William G Iacono · University Of Minnesota · U01 · FY2016 · DA

RCMI@Morgan: Center for Urban Health Disparities Research and Innovation

$4,717,826
Paul B Tchounwou · Morgan State University · U54 · FY2025 · MD

MEB-1170: A New Chemical Entity for the Treatment of Opioid Use Disorder

$4,710,576
Lawrence C Kuo · Mebias Discovery, Inc. · UG3 · FY2025 · DA

The National Drug Abuse Treatment Clinical Trials Network

$4,700,000
Roger D. Weiss · Mclean Hospital · UG1 · FY2019 · DA

Leadership for HIV/AIDS Clinical Trials Networks; HIV Prevention Trials Network

$4,687,361
Thomas R Fleming · Fred Hutchinson Cancer Research Center · U01 · FY2006 · AI

EXERCISE THE OPTION ITEM UNDER THE CLINICAL TRIALS NETWORK CLINICAL COORDINATING CENTER. JULY 6, 2022 - JULY 5, 2023. TASK ORDER 6

$4,683,571
Eve Jelstrom · The Emmes Company, Llc · N01 · FY2022 · DA

The Collaboration Linking Opioid Use Disorder and Sleep ("CLOUDS") Study

$4,672,265
Henry Klar Yaggi · Yale University · U01 · FY2019 · HL

SDSU FUERTE: Faculty United towards Excellence in Research and Transformational Engagement

$4,668,857
Maria Luisa Zuniga De Nuncio · San Diego State University · U54 · FY2024 · CA

Design and synthesis of drugs acting on central and peripheral tissues

$4,663,417
Kenner C Rice · National Institute On Drug Abuse · Z01 · FY2007 · DA

TO4. CLINICAL COORDINATING CENTER FOR NIDA'S CLINICAL TRIALS NETWORK. CONTRACT TYPE: IDIQ TASK ORDER. POP: 8/15/24 - 8/14/29

$4,656,081
The Emmes Company, Llc · N01 · FY2025 · DA

Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)

$4,639,701
Lorenzo Leggio · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2018 · AA

FY24 AWARD. NIDA DEVELOPMENTAL STUDIES BIOREPOSITORY AND ANALYSIS CENTER. SEPTEMBER 17, 2024 - SEPTEMBER 16, 2025. N01DA-21-5588. TASK ORDER 75N95024F00001 (TO4).

$4,639,112
Michael Keller · Booz Allen Hamilton · N01 · FY2024 · DA

Developing small molecules to engage an analgesic GPCR in pain unpleasantness neural circuits

$4,637,933
Gregory Scherrer · Univ Of North Carolina Chapel Hill · U19 · FY2024 · NS

Neuronal connectivity within the mesolimbic system

$4,635,053
Marisela Morales · National Institute On Drug Abuse · ZIA · FY2022 · DA

Arylepoxamides: A new class of potent, safer analgesics

$4,628,029
Jeffrey Reich · Sparian Biosciences, Inc. · UH3 · FY2022 · DA

Multilevel Interventions to Reduce Harm and Improve Quality of Life for Patients on Long Term Opioid Therapy - Yale Resource Center (MIRHIQL-YRC)

$4,626,338
William C Becker · Yale University · U24 · FY2023 · DA

IMPETUS: Integrated Mechanisms, Phenotypes, and Translational Underpinnings of Chronic Pain after Surgery

$4,618,885
Simon Haroutounian · Washington University · RM1 · FY2024 · NS